Janssen opens new biomanufacturing building in Ireland

8 Oct 2019

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

Janssen Sciences Ireland UC, part of the Johnson & Johnson family of companies, has officially opened its new manufacturing building in Ringaskiddy, Co. Cork. The company has operated a biopharmaceutical supply chain facility on its 40-hectare site in Ringaskiddy since 2005.

Janssen opens new biomanufacturing building in Ireland

The expansion of the biomanufacturing site increases the company’s production capacity by an additional 19,100 m2 and creates 200 new full-time jobs. Approximately 450 people were employed on-site during the 2-year construction project.

The official opening ceremony for the facility was attended by Simon Coveney TD, An Tánaiste and Minister for Foreign Affairs & Trade, Kathy Wengel, Executive Vice-President and Chief Global Supply Chain Officer, Johnson & Johnson and Martin Shanahan, CEO, IDA Ireland.

Speaking at the event, An Tánaiste Simon Coveney TD, said: “I’m delighted to attend the official opening of Janssen’s new manufacturing building, which marks the company’s ongoing commitment to Ireland and patients around the world. The life sciences industry makes a hugely significant contribution to the national economy in terms of jobs and exports. In 2018 alone, 33% of Ireland’s total exports were pharmaceutical and medical products, with Johnson & Johnson featuring as one of our single largest exporters. Finally, I would like to extend my congratulations to the team here in completing this exciting expansion and I wish them continued success in the future.”

Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson said: “Our manufacturing facilities in Cork are at the cutting-edge of delivering healthcare solutions, which is an important part of our Credo commitment to provide the highest quality products to patients. Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions that advance how medicines are manufactured so that we can be at the forefront of treating, preventing, intercepting and curing some of the world’s most devastating and complex diseases.”

Martin Shanahan, CEO, IDA Ireland, said: “Johnson & Johnson is one of the largest life sciences and R&D investors in Ireland and is part of a thriving Biopharma sector in Cork. With a significant investment in expanding Janssen’s manufacturing capacity here in Ringaskiddy, the positive economic spin-off for the South-West region is considerable. On behalf of IDA Ireland, I would like to congratulate the Janssen team on successfully delivering a new, state-of-the-art manufacturing building in the heart of Cork’s life sciences hub.”

Read More

Related tags

Market News

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Allergan expands Refresh eye treatment portfolio

Allergan expands Refresh eye treatment portfolio

7 Oct 2019

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Read more 
BASF strengthens biotechnology footprint to enter natural F&F ingredients market

BASF strengthens biotechnology footprint to enter natural F&F ingredients market

3 Oct 2019

Market entrance with biotech-based natural vanillin, valencene and nootkatone.

Read more 
Unidose device approved for Tosymra sumatriptan spray

Unidose device approved for Tosymra sumatriptan spray

3 Oct 2019

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
BASF's new bioactive ingredient the wellness elixir for healthy skin

BASF's new bioactive ingredient the wellness elixir for healthy skin

1 Oct 2019

The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more 
Industry on the brink of a new age of smart pharma manufacturing

Industry on the brink of a new age of smart pharma manufacturing

27 Sep 2019

Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

Read more